Search
for
Sort by
Research 301–330 of 846
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Hyperandrogenic Disorders
- Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review)
- Sodium Metabisulfite: Effects on Ionic Currents and Excitotoxicity
- Prevention of Male Late-Onset Hypogonadism by Natural Polyphenolic Antioxidants
- A Review of the Most Common Dermatologic Conditions and their Debilitating Psychosocial Impacts
- Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease
- Update on the Potential of <i>Punica granatum</i> L. Traditional Uses and Pharmacological Uses: A Review
- The association of medications and supplements with human male reproductive health: a systematic review
- Cellular senescence and polycystic ovary syndrome: mechanisms and therapeutic strategies from a new perspective
- Ovarian vein sampling, and serum and urine testosterone monitoring in ovarian Leydig cell tumors: A report of two cases
- Hyaluronic Acid Profhilo® Alleviates Skin Inflammation and Spinal Neuroimmune Alterations in a Mouse Model of Atopic Dermatitis
- Understanding the Secular Decline in Testosterone: Mechanisms, Consequences, and Clinical Perspectives
- Novel Synthetic Steroid Derivatives: Target Prediction and Biological Evaluation of Antiandrogenic Activity
- Green and Emerging Microextraction Strategies for Bioanalytical Determination of Hormones: Trends, Challenges, and Applications
- Diagnosis of polycystic ovaries syndrome: establishment of reference values of nine hormones on Maglumi X- 8
- Effect of Neurosteroids on Basal and Stress-Induced Oxytocin Secretion in Luteal-Phase and Pregnant Sheep
- (PNM-35) Recurrent priapism in a sickle cell disease patient treated with gonadotropin-releasing hormone (GnRH) agonists drugs: a case report
- Affect of a six months treatment regiment of metformin (MET) on 17-hydroxyprogesterone (17P) responses to GnRH agonist (GnRH Ag) in polycystic ovary syndrome (PCOS)
- Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
- Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- Intratesticular Control Of Steroidogenesis
- Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗
- Polycystic ovary syndrome and impact on health
- Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
- Management of Hirsutism
- Kisspeptin and LH pulsatile temporal coupling in PCOS patients
- Differential Suppression of Testosterone and Estradiol in Hirsute Women With the Superactive Gonadotropin-Releasing Hormone Agonist Leuprolide*
- Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission
- Cardiovascular Toxicities of Androgen Deprivation Therapy